Literature DB >> 8385573

Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma.

C Pyke1, N Graem, E Ralfkiaer, E Rønne, G Høyer-Hansen, N Brünner, K Danø.   

Abstract

Histological samples from 60 invasive ductal breast carcinomas were investigated for immunoreactivity for the receptor for urokinase-type plasminogen activator (uPAR) with the use of two monoclonal antibodies recognizing different epitopes. In 51 cases, uPAR immunoreactivity was observed, and in 49 of these specimens, a population of periductal tissue macrophages showed pronounced uPAR immunoreactivity in areas with infiltrating and intraductal carcinoma. In the 2 remaining positive specimens no stromal immunoreactivity was seen. The carcinoma cells were found to contain uPAR immunoreactivity in 8 of the 51 positive cases, including the two specimens that did not show stromal immunostaining. Immunoactivity was not found in the epithelial cells of carcinoma in situ components occasionally seen in the specimens, but stromal macrophage-like cells which had invaded such lesions were positive. In most specimens a subpopulation of tissue neutrophils was also positive. Normally appearing epithelium in all specimens investigated was negative, and no other tissue elements were stained in any of the samples. Ten samples of normal female breast tissue were negative. This is the first report on the immunohistochemical distribution of uPAR in human cancer tissue, and the results provide evidence for a role of the urokinase receptor in providing tissue macrophages a means of directing proteolysis at sites of breast cancer invasion. This macrophage-mediated proteolytic activity is suggested to be involved in the invasion and subsequent distant spreading of this malignancy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8385573

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

Review 1.  Tumor-associated macrophages in breast cancer.

Authors:  Russell D Leek; Adrian L Harris
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.673

2.  Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas.

Authors:  I Bolon; M Devouassoux; C Robert; D Moro; C Brambilla; E Brambilla
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

3.  Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.

Authors:  Kasper Almholt; Ole Didrik Lærum; Boye Schnack Nielsen; Ida Katrine Lund; Leif Røge Lund; John Rømer; Annika Jögi
Journal:  Clin Exp Metastasis       Date:  2015-06-04       Impact factor: 5.150

Review 4.  Oligonucleotide-based theranostic nanoparticles in cancer therapy.

Authors:  Reza Shahbazi; Bulent Ozpolat; Kezban Ulubayram
Journal:  Nanomedicine (Lond)       Date:  2016-04-22       Impact factor: 5.307

Review 5.  Diverse Applications of Nanomedicine.

Authors:  Beatriz Pelaz; Christoph Alexiou; Ramon A Alvarez-Puebla; Frauke Alves; Anne M Andrews; Sumaira Ashraf; Lajos P Balogh; Laura Ballerini; Alessandra Bestetti; Cornelia Brendel; Susanna Bosi; Monica Carril; Warren C W Chan; Chunying Chen; Xiaodong Chen; Xiaoyuan Chen; Zhen Cheng; Daxiang Cui; Jianzhong Du; Christian Dullin; Alberto Escudero; Neus Feliu; Mingyuan Gao; Michael George; Yury Gogotsi; Arnold Grünweller; Zhongwei Gu; Naomi J Halas; Norbert Hampp; Roland K Hartmann; Mark C Hersam; Patrick Hunziker; Ji Jian; Xingyu Jiang; Philipp Jungebluth; Pranav Kadhiresan; Kazunori Kataoka; Ali Khademhosseini; Jindřich Kopeček; Nicholas A Kotov; Harald F Krug; Dong Soo Lee; Claus-Michael Lehr; Kam W Leong; Xing-Jie Liang; Mei Ling Lim; Luis M Liz-Marzán; Xiaowei Ma; Paolo Macchiarini; Huan Meng; Helmuth Möhwald; Paul Mulvaney; Andre E Nel; Shuming Nie; Peter Nordlander; Teruo Okano; Jose Oliveira; Tai Hyun Park; Reginald M Penner; Maurizio Prato; Victor Puntes; Vincent M Rotello; Amila Samarakoon; Raymond E Schaak; Youqing Shen; Sebastian Sjöqvist; Andre G Skirtach; Mahmoud G Soliman; Molly M Stevens; Hsing-Wen Sung; Ben Zhong Tang; Rainer Tietze; Buddhisha N Udugama; J Scott VanEpps; Tanja Weil; Paul S Weiss; Itamar Willner; Yuzhou Wu; Lily Yang; Zhao Yue; Qian Zhang; Qiang Zhang; Xian-En Zhang; Yuliang Zhao; Xin Zhou; Wolfgang J Parak
Journal:  ACS Nano       Date:  2017-03-14       Impact factor: 15.881

6.  Urokinase type plasminogen activator receptor expression in colorectal neoplasms.

Authors:  S Suzuki; Y Hayashi; Y Wang; T Nakamura; Y Morita; K Kawasaki; K Ohta; N Aoyama; S R Kim; H Itoh; Y Kuroda; W F Doe
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

7.  1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro.

Authors:  C M Hansen; T L Frandsen; N Brünner; L Binderup
Journal:  Clin Exp Metastasis       Date:  1994-05       Impact factor: 5.150

8.  Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles.

Authors:  Lily Yang; Hui Mao; Zehong Cao; Y Andrew Wang; Xianghong Peng; Xiaoxia Wang; Hari K Sajja; Liya Wang; Hongwei Duan; Chunchun Ni; Charles A Staley; William C Wood; Xiaohu Gao; Shuming Nie
Journal:  Gastroenterology       Date:  2009-01-14       Impact factor: 22.682

9.  The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.

Authors:  Minji Jo; Shinako Takimoto; Valerie Montel; Steven L Gonias
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

10.  A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

Authors:  N Pedersen; M Schmitt; E Rønne; M I Nicoletti; G Høyer-Hansen; M Conese; R Giavazzi; K Dano; W Kuhn; F Jänicke
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.